莫诺拉韦与新冠急性后遗症风险:队列研究
该研究基于美国退伍军人事务部数据,纳入2022年1月5日至2023年1月15日间SARS-CoV-2检测阳性、至少有一个重症危险因素且存活超过30天的229 286名参与者,其中11 472人在阳性后5天内收到莫诺拉韦处方,217 814人未接受抗病毒或抗体治疗。经逆概率加权平衡后,莫诺拉韦组PASC相对风险0.86(95%CI 0.83-0.89),180天绝对风险降低2.97%(95%CI 2.31%-3.60%);急性期后死亡HR 0.62(95%CI 0.52-0.74),绝对风险降低0.87%(95%CI 0.62%-1.13%);急性期后住院RR 0.86(95%CI 0.80-0.93),绝对风险降低1.32%(95%CI 0.72%-1.92%)。莫诺拉韦还与13种急性后遗症中8种的风险降低相关。作者认为,在重症高危人群中,感染后5天内使用莫诺拉韦可能是降低PASC风险的可行方法。
要点
- 在具有至少一个重症危险因素的新冠感染者中,阳性后5天内使用莫诺拉韦与PASC风险降低相关:RR 0.86(95%CI 0.83-0.89),180天绝对风险降低2.97%(95%CI 2.31%-3.60%)。
- 莫诺拉韦与急性期后死亡风险降低相关:HR 0.62(95%CI 0.52-0.74),180天绝对风险降低0.87%(95%CI 0.62%-1.13%)。
- 莫诺拉韦与急性期后住院风险降低相关:RR 0.86(95%CI 0.80-0.93),180天绝对风险降低1.32%(95%CI 0.72%-1.92%)。
- 莫诺拉韦与13种急性后遗症中8种风险降低相关:心律失常、肺栓塞、深静脉血栓、疲劳与乏力、肝病、急性肾损伤、肌肉疼痛和神经认知障碍。
- 在未接种疫苗、接种1或2剂疫苗、接种加强针者中,以及原发感染和再感染者中,莫诺拉韦均与PASC风险降低相关。
适用人群与场景
- 2022年1月5日至2023年1月15日期间SARS-CoV-2检测阳性、至少有一个进展为重症covid-19的危险因素、且存活超过检测阳性后30天的美国退伍军人事务部参与者229 286人。
- 莫诺拉韦组:阳性检测结果后5天内收到莫诺拉韦处方的11 472人;无治疗组:未接受任何covid-19抗病毒或抗体治疗的217 814人。
- 亚组包括未接种covid-19疫苗者、接种1或2剂疫苗者、接种加强针者,以及原发SARS-CoV-2感染者和再感染者。
诊断标准与关键阈值
- PASC定义为基于预先指定的13种急性后遗症。
- 急性期后结局从首次SARS-CoV-2阳性检测结果后30天开始 ascertain 至随访结束。
处置流程与药物剂量
- 莫诺拉韦在SARS-CoV-2阳性检测结果后5天内处方;原文未报告具体剂量、给药途径和频次。
研究设计与关键结果
- 研究设计:队列研究,设置于美国退伍军人事务部,纳入229 286名参与者,莫诺拉韦组11 472人,无治疗组217 814人,应用逆概率加权平衡两组。
- 主要终点:与无治疗相比,阳性后5天内使用莫诺拉韦与PASC风险降低相关:相对风险0.86(95%CI 0.83-0.89),180天绝对风险降低2.97%(95%CI 2.31%-3.60%)。
- 急性期后死亡:HR 0.62(95%CI 0.52-0.74),180天绝对风险降低0.87%(95%CI 0.62%-1.13%)。
- 急性期后住院:RR 0.86(95%CI 0.80-0.93),180天绝对风险降低1.32%(95%CI 0.72%-1.92%)。
- 13种急性后遗症中8种风险降低:心律失常、肺栓塞、深静脉血栓、疲劳与乏力、肝病、急性肾损伤、肌肉疼痛、神经认知障碍。
- 亚组:在未接种疫苗、接种1或2剂疫苗、接种加强针者中,以及原发感染和再感染者中,莫诺拉韦均与PASC风险降低相关。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在进展为重症covid-19高风险人群中,SARS-CoV-2感染后5天内使用莫诺拉韦可能是降低PASC风险的可行方法。
- 研究显示莫诺拉韦与PASC、急性期后死亡和急性期后住院风险降低相关,适用于具有至少一个重症危险因素且存活超过30天的SARS-CoV-2感染者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To examine whether treatment with the antiviral agent molnupiravir during the first five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse health outcomes.
DESIGN: Cohort study.
SETTING: US Department of Veterans Affairs.
PARTICIPANTS: 229 286 participants who tested positive for SARS-CoV-2 between 5 January 2022 and 15 January 2023, had at least one risk factor for progression to severe covid-19, and survived the first 30 days after testing positive were enrolled. 11 472 participants received a prescription for molnupiravir within five days of the positive test result and 217 814 received no covid-19 antiviral or antibody treatment (no treatment group).
MAIN OUTCOME MEASURES: Risks of post-acute sequelae of SARS-CoV-2 (PASC, defined based on a prespecified set of 13 post-acute sequelae), post-acute death, post-acute hospital admission, and each individual post-acute sequela between the molnupiravir group and no treatment group were examined after application of inverse probability weighting to balance the treatment and no treatment groups. Post-acute outcomes were ascertained from 30 days after the first SARS-CoV-2 positive test result until end of follow-up. Risks on the relative scale (relative risk or hazard ratio) and absolute scale (absolute risk reduction at 180 days) were estimated.
RESULTS: Compared with no treatment, molnupiravir use within five days of a positive SARS-CoV-2 test result was associated with reduced risk of PASC (relative risk 0.86 (95% confidence interval 0.83 to 0.89); absolute risk reduction at 180 days 2.97% (95% confidence interval 2.31% to 3.60%)), post-acute death (hazard ratio 0.62 (0.52 to 0.74); 0.87% (0.62% to 1.13%)), and post-acute hospital admission (0.86 (0.80 to 0.93); 1.32% (0.72% to 1.92%)). Molnupiravir was associated with reduced risk of eight of the 13 post-acute sequelae: dysrhythmia, pulmonary embolism, deep vein thrombosis, fatigue and malaise, liver disease, acute kidney injury, muscle pain, and neurocognitive impairment. Molnupiravir was also associated with reduced risk of PASC in people who had not received a covid-19 vaccine, had received at one or two vaccine doses, and had received a booster dose, and in people with primary SARS-CoV-2 infection and reinfection.
CONCLUSIONS: In people with SARS-CoV-2 infection and at least one risk factor for progression to severe covid-19, compared with no treatment, molnupiravir use within five days of infection was associated with reduced risk of PASC in people who had not received a covid-19 vaccine, had received one or two vaccine doses, and had received a booster dose, and in those with primary SARS-CoV-2 infection and reinfection. Among people at high risk of progression to severe covid-19, molnupiravir use within five days of SARS-CoV-2 infection may be a viable approach to reduce the risk of PASC.
参考来源
- Xie Y, Choi T, Al-Aly Z, et al. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023. PMID: 37161995. doi:10.1136/bmj-2022-074572
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。